Jun 1, 2026.
On 28 May 2026, the IN-ARMOR consortium successfully held its 13th Management Board Meeting (MBM13). The online gathering brought together work package leaders and key representatives from our 16 partner organizations to evaluate the project’s recent milestones and outline the strategic roadmap for the coming months.
As IN-ARMOR recently closed its Second Reporting Period (RP2) in April 2026, today’s meeting heavily focused on the preparations for the highly anticipated Second Project Review Meeting (PR2) with the European Commission. This crucial technical review is officially scheduled for the first week of July 2026.
Key Highlights and Ongoing Progress:
During the meeting, the Management Board reviewed the significant advancements made across all Work Packages (WPs) in the fight against antimicrobial resistance (AMR) using our innovative immune system inducers (ISI):
Upcoming 4th Consortium Meeting:
The board also advanced the logistical and strategic planning for the upcoming 4th IN-ARMOR Consortium Meeting. This major in-person event will take place in Madrid, Spain, hosted by our clinical partner, the Madrilenian Health Service (SERMAS).
For more updates on our research, publications, and upcoming events, continue to follow us here at https://inarmor-project.eu/ and on our social media channels.
